

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/081799 A1

(51) International Patent Classification:

A61K 31/138 (2006.01) A61K 31/282 (2006.01)
A61K 31/196 (2006.01) A61K 31/337 (2006.01)
A61K 31/28 (2006.01)

(21) International Application Number:

PCT/US2021/054907

(22) International Filing Date:

14 October 2021 (14.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/091,839	14 October 2020 (14.10.2020)	US
63/201,978	21 May 2021 (21.05.2021)	US
63/260,130	10 August 2021 (10.08.2021)	US
63/261,742	28 September 2021 (28.09.2021)	US

(71) Applicant: **VIRIDIAN THERAPEUTICS, INC.**

[US/US]; 203 Crescent Street, Bldg. 17, Suite 102b,
Waltham, Massachusetts 02453 (US).

(72) Inventors: **BEDIAN, Vahe**; 203 Crescent Street, Building 17, Suite 102b, Waltham, Massachusetts 02453 (US).

HARWIN, Peter; 203 Crescent Street, Building 17, Suite

102b, Waltham, Massachusetts 02453 (US). **KISELAK, Tomas**; 203 Crescent Street, Building 17, Suite 102b, Waltham, Massachusetts 02453 (US). **SHE, Angela**; 203 Crescent Street, Building 17, Suite 102b, Waltham, Massachusetts 02453 (US). **VIOLIN, Jonathan**; 203 Crescent Street, Building 17, Suite 102b, Waltham, Massachusetts 02453 (US). **ZHAO, Yang**; 203 Crescent Street, Building 17, Suite 102b, Waltham, Massachusetts 02453 (US).

(74) Agent: **SCOLNICK, Daniel, M.**; Troutman Pepper Hamilton Sanders LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, Pennsylvania 19312 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE

VRDN-2700 AND Teprotumumab
NHP Serum Concentration




FIG. 1

(57) Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*